NEW YORK, Feb. 6, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025.So what: If you purchased GSK ADRs during the Class Per ...

GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press around changes that the new Trump Administration will be brining.. This article will look at why this stock is a Zacks Rank #5 (Strong Sell) as it is the Bear of the Day.Description                        GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical ...

Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering.GSK plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bact ...

SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK) between February 5, 2020 and August 14, 2022.  GSK is a global pharmaceutical company that develops, manufactures, and markets vaccines and medicines worldwide.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating A ...

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Rec ...

5 February 2025 FY 2024 Results Conference call and webcast for investors and analysts gsk.com Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project' ...

Key TakeawaysGSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs.The British drugs giant said it expects 2031 revenue to be more than 40 billion pounds.GSK's fourth-quarter core earnings per share and revenue also beat estimates. GSK Plc's (GSK) U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a  stock ...

GSK plc (NYSE:GSK) Q4 2024 Earnings Conference Call February 5, 2025 5:45 AM ET Company Participants Dame Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Julie Brown - Chief Financial Officer David Redfern - President Corporate Development Tony Wood - Chief Scientific Officer Conference Call Participants Emily Field - Barclays Bank Richard Parkes - BNPP Exane Peter Welford - Jefferies Steve Scala - TD Cowen Rajan Sharma - Goldman Sachs Justin Smith - Bernstein Graham Parry - Ba ...

GSK plc (GSK) reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year on a reported basis and 10% at a constant exchange rate (CER) due to increased operating expenses during the quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Quarterly revenues rose 1% on a reported basis and 4% at CER to $10.4 billion (£8.12 billion). The top line outpaced the Zacks ...

Company Performance - GSK reported quarterly earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.53 per share, but down from $0.72 per share a year ago, representing an earnings surprise of 11.32% [1] - The company posted revenues of $10.4 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.04%, compared to year-ago revenues of $10 billion [2] - Over the last four quarters, GSK has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Future Outlook - The sustainability of GSK's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - Current consensus EPS estimate for the coming quarter is $1.11 on revenues of $9.67 billion, and for the current fiscal year, it is $4.07 on revenues of $40.5 billion [7] - The estimate revisions trend for GSK is currently unfavorable, resulting in a Zacks Rank 5 (Strong Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which GSK belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]